Payer Evidence Requirements: What Coverage Decisions Actually Demand

← Back to All Insights

Sponsors often generate the clinical evidence FDA requires for approval and then discover that payers want something different. The evidence required to clear a device is not always the evidence required to cover it. Understanding the evidence-generation framework payers actually apply—before the clinical trial finishes design—saves years and tens of millions of dollars.

FDA evaluates safety and effectiveness. Payers evaluate net health benefit relative to alternatives, often within an explicit cost framework FDA does not consider.

The Three Evidence Questions Payers Ask

Does the technology improve net health outcomes compared to standard of care? In what specific patient population? At what incremental cost per quality-adjusted life year? FDA's safety and effectiveness questions are necessary but not sufficient to answer the three payer questions. Comparative effectiveness, defined populations, and cost-effectiveness analysis fill the gap.

ICER and the Comparative Effectiveness Frame

The Institute for Clinical and Economic Review (ICER) has emerged as an influential US-side evaluator of comparative effectiveness. ICER evidence reports are increasingly cited by commercial payers in coverage decisions. Sponsors who plan around FDA-required evidence and ignore ICER often discover the evidence base is inadequate for payer purposes.

Real-World Evidence in Coverage Decisions

Payers increasingly accept real-world evidence (RWE) to supplement pivotal trial data, particularly for indications expansion or maintained coverage. The evidence quality requirements are specific: identifiable patient populations, reliable outcome ascertainment, comparable control groups, and pre-specified analysis plans. Casual RWE rarely persuades.

Cost-Effectiveness Analysis Standards

US payers historically resisted formal cost-effectiveness thresholds. That has shifted. Many commercial payers now apply an implicit $50,000-$150,000 per quality-adjusted life year (QALY) threshold to coverage decisions. Therapeutics and devices above the threshold face increasing prior authorization, step therapy, or outright non-coverage.

Evidence Generation Strategy

Sponsors who plan evidence generation only for FDA submission consistently underinvest in payer-required evidence. Disciplined sponsors run parallel evidence streams: pivotal trial for FDA approval, comparative effectiveness for payer coverage, cost-effectiveness model for value demonstration, and post-approval real-world evidence for coverage expansion. The four streams require different study designs and different operational capabilities.

Diligence Implications

Investors evaluating medical device or therapeutics companies should examine whether the evidence-generation plan supports both FDA approval and payer coverage. Pivotal trial design that ignores comparative effectiveness or cost-effectiveness considerations typically results in expensive post-approval evidence gaps that delay revenue ramp.

Payer evidence requirements are predictable, specific, and increasingly important. Companies that build evidence-generation plans around the FDA submission alone consistently find themselves generating expensive post-approval evidence under commercial pressure. Companies that plan for payer evidence requirements from Phase 2 / pivotal trial design onward consistently achieve faster post-approval revenue ramps.